Skip to Content

Lufyllin-EPG (dyphylline / ephedrine / guaifenesin / phenobarbital) and Alcohol / Food Interactions

There are 3 alcohol/food/lifestyle interactions with Lufyllin-EPG (dyphylline / ephedrine / guaifenesin / phenobarbital) which include:

Major

PHENobarbital ↔ Alcohol (Ethanol)

Major Drug Interaction

Ask your doctor before using PHENobarbital together with ethanol, this can add to dizziness, drowsiness and other side effects of PHENobarbital. Be careful if you drive or do activities that require you to be awake and alert. Talk with your doctor before using any medications together, or drinking alcohol with PHENobarbital. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Minor

ePHEDrine ↔ Alcohol (Ethanol)

Minor Drug Interaction

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

For clinical details see professional interaction data.

Major

High Blood Pressure (Hypertension)

Severe Potential Hazard, Moderate plausibility

barbiturates IV - cardiovascular

The intravenous administration of barbiturates may produce severe cardiovascular reactions such as bradycardia, hypertension, or vasodilation with fall in blood pressure, particularly during rapid infusion. Parenteral therapy with barbiturates should be administered cautiously in patients with hypertension, hypotension, or cardiac disease. The intravenous administration of barbiturates should be reserved for emergency treatment of acute seizures or for anesthesia.

References

  1. "Product Information. Amytal Sodium (amobarbital)" Lilly, Eli and Company, Indianapolis, IN.
  2. "Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company, Indianapolis, IN.
  3. "Product Information. Nembutal Sodium (pentobarbital)" Abbott Pharmaceutical, Abbott Park, IL.
  4. "Product Information. Seconal Sodium (secobarbital)" Lilly, Eli and Company, Indianapolis, IN.
  5. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
View all 5 references
Moderate

High Blood Pressure (Hypertension)

Moderate Potential Hazard, Moderate plausibility

dyphylline - cardiotoxicity

Like other methylxanthines, dyphylline at high dosages may be associated with positive inotropic and chronotropic effects on the heart. Therapy with dyphylline and products containing dyphylline should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or recent myocardial infarction. The relationship between plasma dyphylline levels and therapeutic as well as toxic effects has not been determined.

References

  1. "Multum Information Services, Inc. Expert Review Panel"
  2. "Product Information. Lufyllin (dyphylline)" Wallace Laboratories, Cranbury, NJ.

Lufyllin-EPG (dyphylline / ephedrine / guaifenesin / phenobarbital) drug interactions

There are 1383 drug interactions with Lufyllin-EPG (dyphylline / ephedrine / guaifenesin / phenobarbital)

Lufyllin-EPG (dyphylline / ephedrine / guaifenesin / phenobarbital) disease interactions

There are 22 disease interactions with Lufyllin-EPG (dyphylline / ephedrine / guaifenesin / phenobarbital) which include:

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide